Janid A Ali from 605 Putnam Ave #2, Cambridge, MA 02139, age 56, Phone: 6179451757

Senior Director, Biochemistry- Infinity Pharmaceuticals

view source

Position:

Director at Infinity Pharmaceuticals

Location:

Greater Boston Area

Industry:

Pharmaceuticals

Work:

Infinity Pharmaceuticals
Director
Washington University - Department of Biochemistry & Molecular Biophysics 1993 - 1999
Post Doc

Director

view source

Location:

Cambridge, MA

Industry:

Pharmaceuticals

Work:

Tango Therapeutics Mar 2017 - Mar 2020
Vice President, Biochemistry
Ipi Mar 2013 - Aug 2016
Senior Director, Biochemistry
Ipi Mar 2008 - Feb 2013
Director, Biochemistry
Ipi Mar 2005 - Feb 2008
Associate Director, Biochemistry
Ipi Jul 2003 - Feb 2005
Lead Senior Scientist, Biochemistry

Education:

University of Leicester 1989 - 1993
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy University of East Anglia 1986 - 1989

Skills:

Biochemistry
Drug Discovery
Oncology
Pharmaceutical Industry
Drug Development
Chemistry
Life Sciences
Chromatography
Enzyme Kinetics
Clinical Development
Biotechnology
Molecular Biology
R&D
Cro
Cancer
Medicinal Chemistry
Clinical Trials
High Performance Liquid Chromatography
Lifesciences
Biopharmaceuticals
Hplc
Pharmacology

Director At Infinity Pharmaceuticals

view source

Position:

Director at Infinity Pharmaceuticals

Location:

Greater Boston Area

Industry:

Pharmaceuticals

Work:

Infinity Pharmaceuticals
Director

Us Patents

Drug Discovery Employing Calorimetric Target Triage
view source
US Patent:

20030044800, Mar 6, 2003
Filed:

Sep 4, 2001
Appl. No.:

09/946047
Inventors:

Patrick Connelly - Harvard MA, US
Gregory Connelly - Waltham MA, US
Janid Ali - Waltham MA, US
International Classification:

C12Q001/68
G01N033/53
G06F019/00
G01N033/48
G01N033/50
US Classification:

435/006000, 435/007100, 702/019000
Abstract:

Novel methods for drug discovery including identification of targets and identification of the functions of targets are disclosed. The methods provide for rapid identification and high throughput screening of targets for developing therapeutics to treat disease conditions.

Structure-Based Drug Design Methods For Identifying D-Ala-D-Ala Ligase Inhibitors As Antibacterial Drugs
view source
US Patent:

20030119061, Jun 26, 2003
Filed:

Jun 28, 2002
Appl. No.:

10/186886
Inventors:

Paul Ala - Newark DE, US
Janid Ali - Waltham MA, US
Carlos Faerman - Acton MA, US
James Griffith - Weston MA, US
Andrew Magee - Maynard MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Patrick Connelly - Harvard MA, US
International Classification:

G01N033/53
G06F019/00
G01N033/48
G01N033/50
US Classification:

435/007100, 702/019000
Abstract:

The invention is based on the discovery that certain small molecules can bind to the ATP binding site of D-Ala-D-Ala ligase, even in the absence of the enzyme's substrate, and can cause a conformational change in the enzyme structure similar to that which occurs upon binding of ATP and substrate to the enzyme. Without wishing to be bound by any theory, it is believed that such a conformational change is required for either activation or inhibition of the enzyme. The information obtained from this discovery has enabled identification of key interactions in the active site of the enzyme, as well as the design and opimization of inhibitors.

Novel Heterocyclic Compounds As Selective Bacterial Dhfr Inhibitors And Their Uses Thereof
view source
US Patent:

20030176436, Sep 18, 2003
Filed:

Jun 28, 2002
Appl. No.:

10/184855
Inventors:

Paul Ala - Newark, DE
Janid Ali - Waltham MA, US
Jacob Clement - Vancouver, CA
Carlos Faerman - Acton MA, US
John Gazzaniga - Worcester MA, US
Andrew Magee - Maynard MA, US
Salvatore Marchese - Malden MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Paul Will - Stoneham MA, US
International Classification:

A61K031/525
A61K031/519
C07D475/08
C07D487/02
US Classification:

514/251000, 514/264100, 514/264110, 544/260000, 544/279000
Abstract:

This invention relates to novel heterocyclic compounds and to their use in the medical treatment or prophylaxis of bacterial infections, or their use as antiseptics, sterilizants, or disinfectants.

Heterocyclic Compounds And Uses Thereof As D-Alanyl-D-Alanine Ligase Inhibitors
view source
US Patent:

20030181470, Sep 25, 2003
Filed:

Jun 28, 2002
Appl. No.:

10/185059
Inventors:

Paul Ala - Newark DE, US
Janid Ali - Waltham MA, US
Jacob Clement - Vancouver MA, US
Patrick Connelly - Harvard MA, US
Carlos Faerman - Acton MA, US
Christopher Farady - San Francisco CA, US
John Gazzaniga - Worcester MA, US
Andrew Magee - Maynard MA, US
Salvatore Marchese - Malden MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Paul Will - Stoneham MA, US
International Classification:

A61K031/519
A61K031/517
C07D487/02
C07D239/95
US Classification:

514/262100, 514/264110, 514/266400, 544/256000, 544/279000, 544/291000
Abstract:

The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the bacterial cell-wall synthesis. The compounds can bind to and inhibit the enzyme D-Ala-D-Ala ligase. The new compounds' activity combined with their ability to cross bacterial cell membranes makes them suitable for use as antibacterial drugs or other antibacterial applications.

Structure-Based Drug Design Methods For Identifying D-Ala-D-Ala Ligase Inhibitors As Antibacterial Drugs
view source
US Patent:

20070207512, Sep 6, 2007
Filed:

Aug 1, 2006
Appl. No.:

11/461678
Inventors:

Paul Ala - Newark DE, US
Janid Ali - Waltham MA, US
Carlos Faerman - Acton MA, US
James Griffith - Weston MA, US
Andrew Magee - Maynard MA, US
Scott Moe - Marlborough MA, US
Manuel Navia - Lexington MA, US
Emanuele Perola - Cambridge MA, US
Patrick Connelly - Harvard MA, US
Assignee:

Pliva d.d. - Zagreb
International Classification:

C12Q 1/25
US Classification:

435007710, 435004000
Abstract:

The invention is based on the discovery that certain small molecules can bind to the ATP binding site of D-Ala-D-Ala ligase, even in the absence of the enzyme's substrate, and can cause a conformational change in the enzyme structure similar to that which occurs upon binding of ATP and substrate to the enzyme. Without wishing to be bound by any theory, it is believed that such a conformational change is required for either activation or inhibition of the enzyme. The information obtained from this discovery has enabled identification of key interactions in the active site of the enzyme, as well as the design and opimization of inhibitors.

Heterocyclic Compounds And Uses Thereof As D-Alanyl-D-Alanine Ligase Inhibitors
view source
US Patent:

20080090847, Apr 17, 2008
Filed:

Dec 5, 2007
Appl. No.:

11/951214
Inventors:

Scott Moe - Marlborough MA, US
Paul Ala - Newark DE, US
Emanuele Perola - Cambridge MA, US
Carlos Faerman - Acton MA, US
Jacob Clement - Vancouver, CA
Janid Ali - Waltham MA, US
Paul Will - Stoneham MA, US
Salvatore Marchese - Malden MA, US
Andrew Magee - Maynard MA, US
John Gazzaniga - Worcester MA, US
Christopher Faraday - San Francisco CA, US
Manuel Navia - Lexington MA, US
Patrick Connelly - Harvard MA, US
Assignee:

PLIVA D.D. - Zagreb
International Classification:

A61K 31/495
A61P 33/00
C07D 475/04
C12N 9/99
US Classification:

514262100, 435184000, 544260000
Abstract:

The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the bacterial cell-wall synthesis. The compounds can bind to and inhibit the enzyme D-Ala-D-Ala ligase. The new compounds' activity combined with their ability to cross bacterial cell membranes makes them suitable for use as antibacterial drugs or other antibacterial applications.

Anti-Fatty Acid Amide Hydrolase-2 Antibodies And Uses Thereof
view source
US Patent:

20120115162, May 10, 2012
Filed:

Apr 22, 2010
Appl. No.:

13/265330
Inventors:

Janid A. Ali - Cambridge MA, US
James Brownell - Winchester MA, US
Erin Brophy - Dover NH, US
Thomas T. Tibbitts - Westford MA, US
Assignee:

INFINITY PHARMACEUTICALS, INC. - Cambridge MA
International Classification:

G01N 33/573
C12N 9/99
A61K 38/16
C07K 16/40
C12N 9/80
US Classification:

435 71, 5303879, 5303873, 435228, 530325, 530300, 435184
Abstract:

Antibodies that specifically bind to fatty acid amide hydrolases and methods of using the antibodies are provided herein.